Trial Profile
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ulodesine (Primary) ; Allopurinol; Pneumococcal vaccine; Tetanus vaccine
- Indications Gout; Pneumococcal infections; Tetanus
- Focus Pharmacodynamics; Therapeutic Use
- 14 Nov 2012 Results reporting changes in xanthine and hypoxanthine levels and presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 14 Nov 2012 Extension study results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 09 Jun 2012 Tolerability results presented at the 13th Annual Congress of the European League Against Rheumatism.